留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙酮酸激酶M2在胃癌中的作用

高洋 孙昭 白春梅

高洋, 孙昭, 白春梅. 丙酮酸激酶M2在胃癌中的作用[J]. 协和医学杂志, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
引用本文: 高洋, 孙昭, 白春梅. 丙酮酸激酶M2在胃癌中的作用[J]. 协和医学杂志, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
GAO Yang, SUN Zhao, BAI Chun-mei. The Role of Pyruvate Kinase M2 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274
Citation: GAO Yang, SUN Zhao, BAI Chun-mei. The Role of Pyruvate Kinase M2 in Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 227-231. doi: 10.12290/xhyxzz.20190274

丙酮酸激酶M2在胃癌中的作用

doi: 10.12290/xhyxzz.20190274
详细信息
    通讯作者:

    孙昭  电话:010-69158754, E-mail: jessiesz@126.com

  • 中图分类号: R735.2; R730.2

The Role of Pyruvate Kinase M2 in Gastric Cancer

More Information
    Corresponding author: SUN Zhao   Tel: 86-10-69158754, E-mail: jessiesz@126.com
  • 摘要: 胃癌是最常见的恶性肿瘤之一,其发病率与死亡率均呈较高水平。丙酮酸激酶M2(pyruvate kinase M2, PKM2)是糖酵解过程的关键限速酶,在多种肿瘤组织中表达明显升高,目前认为PKM2与肿瘤的发生、发展密切相关。在胃癌中,PKM2通过参与调节糖酵解途径、介导PI3K/Akt/mTOR信号通路活化、调控基因转录与细胞凋亡,进而促进胃癌细胞的增殖、转移,抑制细胞凋亡,最终加速胃癌的发展,本文将对此进行详细综述。
    作者贡献:高洋负责文献查阅及文章撰写;孙昭、白春梅负责文章修订。
    利益冲突:  无
  • [1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi:  10.3322/caac.21492
    [2] Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol, 1927, 8: 519-530. doi:  10.1085/jgp.8.6.519
    [3] Burk D, Schade AL. On respiratory impairment in cancer cells[J]. Science, 1956, 124: 270-272. http://www.cell.com/servlet/linkout?suffix=e_1_5_1_2_150_2&dbid=8&doi=10.1016/j.tem.2013.03.002&key=13351639&cf=
    [4] Orang AV, Petersen J, McKinnon RA, et al. Micromanag-ing aerobic respiration and glycolysis in cancer cells[J]. Mol Metab, 2019, 23: 98-126. doi:  10.1016/j.molmet.2019.01.014
    [5] Rihan M, Nalla LV, Dharavath A, et al. Pyruvate kinase m2: A metabolic bug in Re-Wiring the tumor microenvironment[J]. Cancer Microenviron, 2019, 12: 149-167. doi:  10.1007/s12307-019-00226-0
    [6] Dong GC, Mao QX, Xia WJ, et al. PKM2 and cancer: The function of PKM2 beyond glycolysis[J]. Oncol Lett, 2016, 11: 1980-1986. doi:  10.3892/ol.2016.4168
    [7] Shiroki T, Yokoyama M, Tanuma N, et al. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism[J]. Cancer Sci, 2017, 108: 931-940. doi:  10.1111/cas.13211
    [8] Hasan D, Gamen E, Abu Tarboush N, et al. PKM2 and HIF-1alpha regulation in prostate cancer cell lines[J]. PLoS One, 2018, 13: e203745. http://www.researchgate.net/publication/327657345_PKM2_and_HIF-1a_regulation_in_prostate_cancer_cell_lines
    [9] Méndez-Lucas A, Li XL, Hu JJ, et al. Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities[J]. Cancer Res, 2017, 77: 4355-4364. doi:  10.1158/0008-5472.CAN-17-0498
    [10] Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452: 230-233. doi:  10.1038/nature06734
    [11] Wong N, Ojo D, Yan J, et al. PKM2 contributes to cancer metabolism[J]. Cancer Lett, 2015, 356: 184-191. doi:  10.1016/j.canlet.2014.01.031
    [12] Chen S, Fisher RC, Signs S, et al. Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis[J]. Oncotarget, 2016, 8: 50476-50488. http://www.ncbi.nlm.nih.gov/pubmed/27286264
    [13] Ying J, Xu Q, Liu BX, et al. The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis[J]. Onco Targets Ther, 2015, 8: 2427-2433. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562727/
    [14] Wei L, Li K, Pang X, et al. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2[J]. J Exp Clin Cancer Res, 2016, 35: 166. doi:  10.1186/s13046-016-0446-4
    [15] Hsu MC, Hung WC. Pyruvate kinase M2 fuels multiple aspects of cancer cells: From cellular metabolism, transcriptional regulation to extracellular signaling[J]. Mol Cancer, 2018, 17: 35. doi:  10.1186/s12943-018-0791-3
    [16] Mukherjee J, Ohba S, See WL, et al. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells[J]. Int J Cancer, 2016, 139: 99-111. doi:  10.1002/ijc.30041
    [17] Yang WW, Xia Y, Ji HT, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation[J]. Nature, 2017, 480: 118-122. http://europepmc.org/articles/PMC3235705
    [18] Gao XL, Wang HZ, Yang JJ, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012, 45: 598-609. doi:  10.1016/j.molcel.2012.01.001
    [19] Luo WB, Hu HX, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell, 2011, 145: 732-744. doi:  10.1016/j.cell.2011.03.054
    [20] Luo WB, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells[J]. Oncotarget, 2011, 2: 551-556. doi:  10.18632/oncotarget.299
    [21] Yang YC, Chien MH, Liu HY, et al. Nuclear translocation of PKM2/AMPK complex sustains cancer stem cell populations under glucose restriction stress[J]. Cancer Lett, 2018, 421: 28-40. doi:  10.1016/j.canlet.2018.01.075
    [22] Liang J, Cao RX, Wang XJ, et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2[J]. Cell Res, 2017, 27: 329-351. doi:  10.1038/cr.2016.159
    [23] Li J, Yang Z, Zou Q, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer[J]. Clin Transl Oncol, 2014, 16: 200-207. doi:  10.1007/s12094-013-1063-8
    [24] Zhan C, Shi Y, Lu C, et al. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer[J]. Dis Esophagus, 2013, 26: 746-753. http://smartsearch.nstl.gov.cn/paper_detail.html?id=42c237bc7ce4dcbb8fba3c3b0efdf8a8
    [25] Feng C, Gao Y, Wang CF, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98: E1524-E1533. doi:  10.1210/jc.2012-4258
    [26] Wang C, Jiang JL, Ji J, et al. PKM2 promotes cell migra-tion and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer[J]. Sci Rep, 2017, 7: 2886. doi:  10.1038/s41598-017-03031-1
    [27] Li H, Xu HY, Xing R, et al. Pyruvate kinase M2 contri-butes to cell growth in gastric cancer via aerobic glycolysis[J]. Pathol Res Pract, 2019, 215: 152409. doi:  10.1016/j.prp.2019.04.001
    [28] Wu JY, Hu L, Chen MY, et al. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: Evidence from 16 cohort studies[J]. Onco Targets Ther, 2016, 9: 4277-4288. doi:  10.2147/OTT.S106508
    [29] Gao YS, Xu DY, Yu GZ, et al. Overexpression of metabolic markers HK1 and PKM2 contributes to lymphatic metastasis and adverse prognosis in Chinese gastric cancer[J]. Int J Clin Exp Pathol, 2015, 8: 9264-9271. http://old.med.wanfangdata.com.cn/viewHTMLEn/PeriodicalPaper_PM26464675.aspx
    [30] Lim JY, Yoon SO, Seol SY, et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer[J]. World J Gastroenterol, 2012, 18: 4037-4043. doi:  10.3748/wjg.v18.i30.4037
    [31] Kato Y, Yashiro M, Noda S, et al. Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma[J]. Br J Cancer, 2010, 102: 898-907. doi:  10.1038/sj.bjc.6605543
    [32] Kitayama K, Yashiro M, Morisaki T, et al. Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer[J]. Cancer Sci, 2017, 108: 2462-2469. doi:  10.1111/cas.13421
    [33] Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene, 2010, 29: 625-634. doi:  10.1038/onc.2009.441
    [34] Melillo G. Targeting hypoxia cell signaling for cancer therapy[J]. Cancer Metastasis Rev, 2007, 26: 341-352. doi:  10.1007/s10555-007-9059-x
    [35] Chen GX, Feng W, Zhang S, et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signal-ing[J]. Am J Cancer Res, 2015, 5: 1423-1434. http://europepmc.org/articles/PMC4473320
    [36] Gao SM, Chen M, Wei W, et al. Crosstalk of mTOR/PKM2 and STAT3/c-Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer[J]. J Cell Biochem, 2018. doi: 10.1002/jcb.26915. Epub ahead of print.
    [37] Lu J, Chen M, Gao SM, et al. LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2[J]. Oncol Lett, 2018, 15: 4358-4364. http://europepmc.org/abstract/MED/29541204
    [38] Wu HL, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances[J]. Blood Rev, 2018, 32: 8-28. doi:  10.1016/j.blre.2017.08.004
    [39] Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: Function and dysfunction of its modula-tors and targeted therapeutic strategies[J]. Aging (Albany NY), 2016, 8: 603-619. http://pubmedcentralcanada.ca/pmcc/articles/PMC4925817/
    [40] Kwon OH, Kang TW, Kim JH, et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level[J]. Biochem Biophys Res Commun, 2012, 423: 38-44. doi:  10.1016/j.bbrc.2012.05.063
  • 加载中
计量
  • 文章访问数:  49
  • HTML全文浏览量:  1
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-09
  • 录用日期:  2020-08-20
  • 网络出版日期:  2020-12-30
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回